<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111085">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059265</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00209</org_study_id>
    <secondary_id>NCI-2014-00209</secondary_id>
    <secondary_id>GOG-0283</secondary_id>
    <secondary_id>GOG-0283</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT02059265</nct_id>
  </id_info>
  <brief_title>Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer</brief_title>
  <official_title>A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well dasatinib works in treating patients with persistent
      ovarian, fallopian tube, endometrial, or peritoneal cancer. Dasatinib may shrink patients'
      tumors by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the clinical activity of dasatinib in patients with recurrent or persistent
      ovarian, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma using
      objective tumor response (complete and partial): in patients without loss of BAF250a
      expression and in patients with loss of BAF250a expression.

      SECONDARY OBJECTIVES:

      I. To examine the nature and degree of toxicity in this patient population treated with this
      regimen in patients with and without loss of BAF250a expression.

      II. To examine the progression-free survival and overall survival for this patient
      population receiving dasatinib in patients with and without loss of BAF250a expression.

      TERTIARY OBJECTIVES:

      I. To examine the agreement between BAF250a immunohistochemistry and AT rich interactive
      domain 1A (SWI-like) (ARID1A) mutation status using next generation sequencing performed in
      formalin-fixed, paraffin-embedded tumor tissue.

      OUTLINE:

      Patients receive dasatinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28
      days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years and
      then every 6 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients with objective tumor response rate (complete response [CR] or partial response [PR]) using RECIST version 1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival (PFS)</measure>
    <time_frame>Duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS will be characterized with Kaplan-Meier plots and estimates of the median time until death or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival (OS)</measure>
    <time_frame>From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS will be characterized with Kaplan-Meier plots and estimates of the median time until death or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse effects as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The frequency and severity of all toxicities are tabulated.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ARID1A mutation status in FFPE using next-generation exon-capture sequencing</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>ARID1A mutation status will be tabulated to determine the correlation between BAF250a immunohistochemistry (IHC) and ARID1A mutations.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Endometrial Clear Cell Carcinoma</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Recurrent Endometrial Carcinoma</condition>
  <condition>Recurrent Fallopian Tube Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Recurrent Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dasatinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have recurrent or persistent ovarian, fallopian tube, peritoneum, and
             endometrial clear cell carcinoma; primary tumors must be at least 50% clear cell
             histomorphology in order to be eligible or have a histologically documented
             recurrence with at least 50% clear cell histomorphology; in addition, the tumors
             should be negative for expression of Wilms tumor 1 (WT-1) antigen and estrogen
             receptor (ER) antigen by immunohistochemistry; appropriate tissue sections must be
             available for histologic evaluation for central pathology review by Gynecologic
             Oncology Group (GOG); immunohistochemical stained slides for ER and WT-1 antigen must
             be available for review by GOG

               -  If the primary tumor had at least 50% clear cell histomorphology, a biopsy of
                  the recurrent or persistent tumor is not required; however, immunohistochemical
                  studies of the primary tumor for ER and WT-1 antigens should be performed and
                  the slides submitted to the GOG for review; the percentage of clear cell
                  histomorphology must be documented in the pathology report or in an addendum to
                  the original report; if slides of the primary tumor are not available for review
                  due to disposal of slides by the histology laboratory (typically 10 years after
                  diagnosis), biopsy of recurrent or persistent disease is required

               -  If the primary tumor had less than 50% clear cell histomorphology (or if slides
                  of the primary tumor are not available for review), a biopsy of the recurrent or
                  persistent tumor is required to confirm at least 50% clear cell histomorphology
                  and lack of immuno-reactivity for ER and WT-1 antigens by immunohistochemistry;
                  the percentage of involvement must be documented in the pathology report or in
                  an addendum to the original report

          -  Five unstained formalin-fixed, paraffin-embedded (FFPE) tumor tissue slides (charged,
             5 um) must be submitted to the central study laboratory (i.e., Clinical Laboratory
             Improvement Amendments [CLIA]-certified immuno-pathology laboratory at Memorial
             Sloan-Kettering Cancer Center) for determination of BAF250a immunohistochemistry
             (IHC) status

          -  All patients must have measurable disease; measurable disease is defined by Response
             Evaluation Criteria In Solid Tumors (RECIST) (version 1.1); measurable disease is
             defined as at least one lesion that can be accurately measured in at least one
             dimension (longest diameter to be recorded); each lesion must be &gt;= 10 mm when
             measured by computed tomography [CT], magnetic resonance imaging [MRI] or caliper
             measurement by clinical exam; or &gt;= 20 mm when measured by chest x-ray; lymph nodes
             must be &gt; 15 mm in short axis when measured by CT or MRI

          -  Patients must have had one prior platinum-based chemotherapeutic regimen for
             management of primary disease; patients are allowed to receive, but are not required
             to receive, two additional cytotoxic regimens for management of recurrent or
             persistent disease

          -  Patients must be &gt;= 3 weeks from last chemotherapy or radiation (6 weeks for
             nitrosoureas or mitomycin)

          -  Patients must have progressed on, be ineligible for, or have declined participation
             in GOG-0254 provided that protocol is actively accruing patients

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Creatinine =&lt; 1.5 times the upper limit of normal (ULN) OR

          -  Creatinine clearance &gt;= 60 mL/min/1.73 m^2

          -  Bilirubin =&lt; 1.5 ULN

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase ALT (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             ULN

          -  Patients who are on concomitant medications that are STRONG inducers or inhibitors of
             the cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) enzyme should stop
             2 weeks prior to first dose of dasatinib, if all other eligibility has been confirmed

          -  Corrected QT (QTc) interval on electrocardiogram must be =&lt; 480 msec (Fridericia
             correction)

          -  Patients who have received one prior regimen must have a GOG performance status of 0,
             1 or 2; patients who have received two or more prior regimens must have GOG
             performance status of 0 or 1

          -  Patients who have met the pre-entry requirements

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

        Exclusion Criteria:

          -  Prior treatment with dasatinib, imatinib or nilotinib

          -  As dasatinib can cause fluid shifts, patients with symptomatic effusions (pleural,
             pericardial, or peritoneal) and/or those who have required a procedure for
             symptomatic effusions within 4 weeks of start of dasatinib are ineligible

          -  Patients with a history of cardiac disease including: (1) uncontrolled angina,
             congestive heart failure, or myocardial infarction within six months prior to study
             entry, (2) congenital long QT syndrome, (3) clinical significant ventricular
             arrhythmias

          -  The concomitant use of histamine (H) 2 blockers and proton pump inhibitors (PPIs)
             with dasatinib is not recommended; the use of antacids should be considered in place
             of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy; if
             antacid therapy is needed, the antacid dose should be administered two hours before
             or after the dose of dasatinib; patients who cannot tolerate discontinuation of H2
             blockers or PPIs are ineligible

          -  Therapeutic anticoagulation is not contraindicated, but for those patients on
             therapeutic anticoagulation, alteration in coagulation parameters is expected
             following initiation of dasatinib; for patients on therapeutic anticoagulation,
             coagulation parameters should be assessed weekly for the first cycle following
             initiation of dasatinib, weekly for the first cycle following a dose reduction, and
             weekly for a minimum of two weeks after stopping dasatinib

          -  Patients whose circumstances do not permit completion of the study or the required
             follow-up

          -  Patients who are pregnant or nursing; women of child-bearing potential must agree to
             use adequate contraception (hormonal or barrier method of birth control; abstinence)
             prior to study entry and for the duration of study participation and for 3 months
             after completion of therapy; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately; a negative serum pregnancy test within 72 hours
             of starting drug is required

          -  Patients who have a major surgical procedure, or significant traumatic injury within
             28 days prior to the first date of treatment on this study, or anticipation of need
             for major surgical procedure during the course of the study; patients with placement
             of vascular access device or core biopsy within 7 days prior to the first date of
             treatment on this study

          -  Patients with other invasive malignancies, with the exception of non melanoma skin
             cancer, who had (or have) any evidence of other cancer present within the last 5
             years or whose previous cancer treatment contraindicates this protocol therapy

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Patients who are unable to swallow pills
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hyman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation-Gynecologic Oncology</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert L. Pisani</last_name>
      <phone>650-934-7000</phone>
    </contact>
    <investigator>
      <last_name>Albert L. Pisani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital and Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew E. Green</last_name>
      <phone>770-219-8800</phone>
      <email>cancerpatient.navigator@nghs.com</email>
    </contact>
    <investigator>
      <last_name>Andrew E. Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meaghan E. Tenney</last_name>
      <phone>773-834-7424</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Meaghan E. Tenney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Regional Health Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>Illinois</state>
        <zip>62864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Oncology Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory P. Sutton</last_name>
      <phone>317-338-2194</phone>
    </contact>
    <investigator>
      <last_name>Gregory P. Sutton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center- Scarborough Campus</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher J. Darus</last_name>
      <phone>207-885-7565</phone>
    </contact>
    <investigator>
      <last_name>Christopher J. Darus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Cancer Research Consortium Community Clinical Oncology Program</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesys Hurley Cancer Institute</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegiance Health</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Hospital</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341-2985</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Port Huron</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's of Michigan</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Macomb-Oakland Hospital</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Stella</last_name>
      <phone>734-712-3456</phone>
    </contact>
    <investigator>
      <last_name>Philip J. Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview-Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hutchinson Area Health Care</name>
      <address>
        <city>Hutchinson</city>
        <state>Minnesota</state>
        <zip>55350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital - Healtheast</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Ulm Medical Center</name>
      <address>
        <city>New Ulm</city>
        <state>Minnesota</state>
        <zip>56073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Health Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota CCOP</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic - Saint Louis Park</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Regional Medical Center</name>
      <address>
        <city>Shakopee</city>
        <state>Minnesota</state>
        <zip>55379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeview Hospital</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rice Memorial Hospital</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology and Hematology PA-Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth Cancer Center</name>
      <address>
        <city>Branson</city>
        <state>Missouri</state>
        <zip>65616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phelps County Regional Medical Center</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter C. Morris</last_name>
      <phone>402-354-7939</phone>
      <email>kathryn.bartz@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>Peter C. Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola M. Spirtos</last_name>
      <phone>702-851-4672</phone>
    </contact>
    <investigator>
      <last_name>Nicola M. Spirtos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter C. Lim</last_name>
      <phone>866-513-8227</phone>
    </contact>
    <investigator>
      <last_name>Peter C. Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Hope at Renown Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter C. Lim</last_name>
      <phone>866-513-8227</phone>
    </contact>
    <investigator>
      <last_name>Peter C. Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Hyman</last_name>
      <phone>212-639-7202</phone>
    </contact>
    <investigator>
      <last_name>David M. Hyman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park Ridge Hospital Breast Health Center</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Griffin</last_name>
      <phone>864-512-1000</phone>
    </contact>
    <investigator>
      <last_name>David Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S. Mannel</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S. Mannel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S. Mannel</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S. Mannel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parviz Hanjani</last_name>
      <phone>215-481-2402</phone>
    </contact>
    <investigator>
      <last_name>Parviz Hanjani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnMed Health Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Griffin</last_name>
      <phone>864-512-1000</phone>
    </contact>
    <investigator>
      <last_name>David Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Griffin</last_name>
      <phone>864-512-1000</phone>
    </contact>
    <investigator>
      <last_name>David Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center-Pelham</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Griffin</last_name>
      <phone>864-512-1000</phone>
    </contact>
    <investigator>
      <last_name>David Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Griffin</last_name>
      <phone>864-512-1000</phone>
    </contact>
    <investigator>
      <last_name>David Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Carolina CCOP</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Griffin</last_name>
      <phone>864-512-1000</phone>
    </contact>
    <investigator>
      <last_name>David Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Western Wisconsin</name>
      <address>
        <city>New Richmond</city>
        <state>Wisconsin</state>
        <zip>54017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Boente</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Matthew P. Boente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
    <mesh_term>Adenomyoepithelioma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
